Owing these properties, PlGF has been proposed as a drug target for anti-angiogenic therapy [169,249,250] as PlGF plasma levels and intratumoral expression have been found to correlate with tumor stage, recurrence, metastasis, and survival in different types of cancer. This evidence concerns the gene PGF and neoplasm.